QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:CELU

Celularity (CELU) Stock Price, News & Analysis

$0.46
+0.03 (+6.91%)
(As of 02/23/2024 ET)
Today's Range
$0.43
$0.47
50-Day Range
$0.17
$0.54
52-Week Range
$0.16
$0.89
Volume
441,728 shs
Average Volume
3.78 million shs
Market Capitalization
$89.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CELU stock logo

About Celularity Stock (NASDAQ:CELU)

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

CELU Stock Price History

CELU Stock News Headlines

Celularity Announce 1-for-10 Reverse Stock Split
Celularity to Effect 1-for-10 Reverse Stock Split
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Celularity Announces 1-for-10 Reverse Stock Split
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Celularity Inc. (NASDAQ:CELU) Sees Large Growth in Short Interest
Celularity Releases CEO Letter to Shareholders
See More Headlines
Receive CELU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/02/2024
Today
2/23/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CELU
Fax
N/A
Employees
225
Year Founded
N/A

Profitability

Net Income
$14.19 million
Net Margins
-1,226.72%
Pretax Margin
-1,226.64%

Debt

Sales & Book Value

Annual Sales
$17.98 million
Cash Flow
$0.18 per share
Book Value
$1.34 per share

Miscellaneous

Free Float
153,669,000
Market Cap
$84.00 million
Optionable
Optionable
Beta
0.25

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Robert Joseph Hariri M.D. (Age 65)
    Ph.D., Founder, CEO & Chairman (Leave of Absence)
    Comp: $1.24M
  • Mr. David C. Beers C.F.A. (Age 54)
    Chief Financial Officer
    Comp: $455.02k
  • Mr. John R. Haines (Age 66)
    Senior EVP, Global Manager & Chief Administrative Officer
    Comp: $503.56k
  • Ramji Krishnan
    Chief Technology Officer
  • Carlos Ramirez
    SVP of Investor Relations
  • Mr. Kyle Harold Fletcher Esq. (Age 39)
    Executive VP, General Counsel & Chief Compliance Officer
  • Dr. Stephen A. Brigido D.P.M. (Age 48)
    President of Degenerative Diseases
  • Dr. Adrian Kilcoyne M.B.A. (Age 53)
    M.D., M.P.H., Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs
  • Sharmila Koppisetti M.D.
    Senior Vice President of Clinical Dev. Immunology & Drug Safety
  • Mr. Tim Wilk
    Senior Vice President of Technical Operations














CELU Stock Analysis - Frequently Asked Questions

How have CELU shares performed in 2024?

Celularity's stock was trading at $0.2474 at the start of the year. Since then, CELU shares have increased by 85.9% and is now trading at $0.4599.
View the best growth stocks for 2024 here
.

Are investors shorting Celularity?

Celularity saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 3,280,000 shares, an increase of 59.2% from the January 15th total of 2,060,000 shares. Based on an average trading volume of 2,390,000 shares, the short-interest ratio is presently 1.4 days. Currently, 3.7% of the shares of the company are short sold.
View Celularity's Short Interest
.

When is Celularity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our CELU earnings forecast
.

How were Celularity's earnings last quarter?

Celularity Inc. (NASDAQ:CELU) issued its quarterly earnings results on Tuesday, January, 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $3.79 million for the quarter. Celularity had a negative net margin of 1,226.72% and a positive trailing twelve-month return on equity of 30.79%.

Who are Celularity's major shareholders?

Celularity's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.93%). Insiders that own company stock include Kok Thay Lim and Robert J Hariri.
View institutional ownership trends
.

How do I buy shares of Celularity?

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CELU) was last updated on 2/23/2024 by MarketBeat.com Staff